Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.37 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | PER2 | O15055 | 1/20 | 0.37 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.37 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5036230 | 0.84 | KDM4E (0.51) | KCNN4KCNA5GSK3BKDM4EGABRA1 | |
| SCHEMBL5886035 | 0.81 | KDM4E (0.39) | KCNN4KCNA5GSK3BKDM4EGABRA1 | |
| SCHEMBL3415214 | 0.78 | ALDH1A1 (0.49) | ALDH1A1MEN1KMT2AGAAHTT | |
| SCHEMBL10019242 | 0.78 | KCNN4 (0.41) | KCNN4KCNA5GSK3BKDM4EGABRA1 | |
| SCHEMBL5885687 | 0.77 | KCNN4 (0.42) | KCNN4KCNA5GSK3BPER2CRY1 | |
| SCHEMBL10019239 | 0.77 | KCNN4 (0.41) | KCNN4KCNA5GSK3BKDM4EGABRA1 | |
| SCHEMBL17265581 | 0.75 | MAPK14 (0.45) | KCNN4KCNA5GSK3BFFAR1MEP1A | |
| SCHEMBL29603007 | 0.75 | KCNN4 (0.43) | KCNN4KCNA5GSK3BMAPK1FFAR1 | |
| SCHEMBL28785615 | 0.75 | KCNN4 (0.43) | KCNN4KCNA5GSK3BMAPK1FFAR1 | |
| SCHEMBL5886103 | 0.74 | PDCD1 (0.46) | KCNN4KCNA5KDM4EKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7005437-B2 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2006-02-28 | — | — | US | disclosed |
| EP-1404648-A1 | AMIDINE SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES WITH AN ANTITHROMBOTIC AND FACTOR XA INHIBITING ACTION | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003101942-A1 | AMIDINE SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES WITH AN ANTITHROMBOTIC AND FACTOR XA INHIBITING ACTION | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-11 | — | — | WO | disclosed |
| US-20030045712-A1 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045712-A1 | Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions | F2, F12, F3 | KCNN4 1913/4885KCNA5 2058/4885GSK3B 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.